

**Supplemental Table 2. Immune-related Adverse Events (irAE) and Clinical Course.**

| Patient # | irAE type               | irAE grade | irAE timepoint | Treatment disruption | Treatment discontinuation |
|-----------|-------------------------|------------|----------------|----------------------|---------------------------|
| 1         | Nausea                  | 3          | Week 90        | Yes                  | Yes                       |
| 4         | Pneumonitis             | 4          | Week 84        | Yes                  | No                        |
| 5         | Renal insufficiency     | 4          | Week 24        | Yes                  | Yes                       |
| 6         | Diarrhea                | 3          | Week 6         | No                   | No                        |
| 6         | Vomiting/diarrhea       | 2          | Week 18        | Yes                  | Yes                       |
| 8         | Lipase increase         | 3          | Week 110       | No                   | No                        |
| 9         | Pneumonitis and hypoxia | 3          | Week 18        | Yes                  | No                        |
| 9         | Pneumonitis             | 3          | Week 30        | Yes                  | No                        |
| 9         | Pneumonitis and hypoxia | 3          | Week 36        | Yes                  | Yes                       |
| 14        | Hyperthyroidism         | 3          | Week 6         | Yes                  | No                        |

The first 17 cycles (2 years of therapy) were 6 weeks. After that, it was optional to switch to nivolumab maintenance only and the cycle changes to 4 weeks.